Jeremy Bray was emotional upon learning that the Manitoba government had not budged on his request for funding his crucial medical treatment. Bray, aged 30, suffers from a degenerative condition that progressively impairs his muscle movements. Despite meeting with Health Minister Uzoma Asagwara after petitioning for coverage of his treatment, Bray’s plea was not successful.
Living with Type 2 spinal muscular atrophy, Bray has been relying on the drug risdiplam, marketed as Evrysdi, for over six months. The manufacturer, Roche, had initially provided the drug for free on compassionate grounds, but recently decided to discontinue this support. Bray sought assistance from the NDP government to reverse their decision but was met with disappointment.
The province aimed to use Bray’s positive response to the treatment as evidence to persuade Canada’s Drug Agency (CDA) to recommend the drug for adults over 25. Bray reported improvements in his voice strength, facial expressions, and work stamina as a data consultant. However, the CDA cited insufficient evidence due to the lack of participation by individuals in Bray’s age group in clinical trials.
Expressing hope for a favorable outcome, Bray and his family met with officials, but the province stood firm in its decision. Asagwara emphasized Manitoba’s adherence to the CDA’s guidelines on drug policies. Despite this, other provinces like Quebec, Alberta, and Ontario have supported adults over 25 with similar treatment.
The high cost of the treatment, estimated at $300,000 for the first year, is a significant barrier in Bray’s case. His family believes that financial concerns are influencing Manitoba’s reluctance to provide coverage, despite the proven benefits of the drug. The Progressive Conservatives criticized the government’s decision, calling it heartless and urging for reconsideration.
While Bray’s family remains determined to explore alternative funding options, they are disheartened by the government’s stance. As efforts continue to advocate for Bray’s access to treatment, the family remains hopeful for a positive resolution.